These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 11763324

  • 1. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
    Doi Y, Abe S, Yamamoto H, Horie H, Ohyama H, Satoh K, Tano Y, Ota Y, Miyazawa M, Wakabayashi K, Hashizume S.
    Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
    [Abstract] [Full Text] [Related]

  • 2. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.
    Kersten G, Hazendonk T, Beuvery C.
    Vaccine; 1999 Apr 09; 17(15-16):2059-66. PubMed ID: 10217607
    [Abstract] [Full Text] [Related]

  • 3. Development of inactivated poliovirus vaccine derived from Sabin strains.
    Simizu B, Abe S, Yamamoto H, Tano Y, Ota Y, Miyazawa M, Horie H, Satoh K, Wakabayashi K.
    Biologicals; 2006 Jun 09; 34(2):151-4. PubMed ID: 16679028
    [Abstract] [Full Text] [Related]

  • 4. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
    Sawyer LA, McInnis J, Albrecht P.
    Biologicals; 1993 Jun 09; 21(2):169-77. PubMed ID: 8297601
    [Abstract] [Full Text] [Related]

  • 5. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
    Yang C, Shi H, Zhou J, Liang Y, Xu H.
    Vaccine; 2009 Nov 05; 27(47):6558-63. PubMed ID: 19729087
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM, Ivanov AP, Wells VR, Ivshina AV, Rezapkin GV, Abe S, Potapova SG, Enterline JC, Hashizume S, Chumakov KM.
    J Infect Dis; 2004 Oct 15; 190(8):1404-12. PubMed ID: 15378432
    [Abstract] [Full Text] [Related]

  • 7. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells.
    Haastrup E, Thierry-Carstensen B, Jensen AM, Stellfeld M, Heilmann C.
    Vaccine; 2004 Feb 25; 22(8):958-62. PubMed ID: 15161072
    [Abstract] [Full Text] [Related]

  • 8. [Effect of 2-phenoxyethanol on potency of Sabin inactivated poliomyelitis vaccine and its safety].
    Bian CX, Jiang SD, Yang JY, Sun MB, Xie MX, Zhang XW, Liao GY, Li WD.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar 25; 21(1):44-6. PubMed ID: 17429533
    [Abstract] [Full Text] [Related]

  • 9. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.
    Sanders BP, Oakes Ide L, van Hoek V, Liu Y, Marissen W, Minor PD, Wimmer E, Schuitemaker H, Custers JH, Macadam A, Cello J, Edo-Matas D.
    Vaccine; 2015 Nov 27; 33(48):6611-6. PubMed ID: 26529068
    [Abstract] [Full Text] [Related]

  • 10. Rapid and accurate identification of poliovirus strains used for vaccine production.
    Nijst OE, Mouthaan JJ, Mekkes DR, Jusic E, van der Avoort HG, Metz B.
    J Virol Methods; 2013 Apr 27; 189(1):189-95. PubMed ID: 23434540
    [Abstract] [Full Text] [Related]

  • 11. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
    Verdijk P, Rots NY, van Oijen MG, Oberste MS, Boog CJ, Okayasu H, Sutter RW, Bakker WA.
    Vaccine; 2013 Nov 12; 31(47):5531-6. PubMed ID: 24063976
    [Abstract] [Full Text] [Related]

  • 12. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
    Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T.
    Vaccine; 2007 Oct 10; 25(41):7041-6. PubMed ID: 17825459
    [Abstract] [Full Text] [Related]

  • 13. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.
    Asturias EJ, Dueger EL, Omer SB, Melville A, Nates SV, Laassri M, Chumakov K, Halsey NA.
    J Infect Dis; 2007 Sep 01; 196(5):692-8. PubMed ID: 17674310
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial.
    Liao G, Li R, Li C, Sun M, Li Y, Chu J, Jiang S, Li Q.
    J Infect Dis; 2012 Jan 15; 205(2):237-43. PubMed ID: 22158682
    [Abstract] [Full Text] [Related]

  • 15. Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses.
    Sun M, Li C, Xu W, Liao G, Li R, Zhou J, Li Y, Cai W, Yan D, Che Y, Ying Z, Wang J, Yang H, Ma Y, Ma L, Ji G, Shi L, Jiang S, Li Q.
    Clin Infect Dis; 2017 May 15; 64(10):1317-1325. PubMed ID: 28419204
    [Abstract] [Full Text] [Related]

  • 16. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine.
    Dragunsky EM, Ivanov AP, Abe S, Potapova SG, Enterline JC, Hashizume S, Chumakov KM.
    J Infect Dis; 2006 Sep 15; 194(6):804-7. PubMed ID: 16941347
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity of enhanced potency inactivated polio vaccine.
    Singh J, Ravi RN, Dutta AK, Kumari S, Khare S.
    Indian Pediatr; 1992 Nov 15; 29(11):1353-6. PubMed ID: 1338200
    [Abstract] [Full Text] [Related]

  • 18. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
    Bakker WA, Thomassen YE, van't Oever AG, Westdijk J, van Oijen MG, Sundermann LC, van't Veld P, Sleeman E, van Nimwegen FW, Hamidi A, Kersten GF, van den Heuvel N, Hendriks JT, van der Pol LA.
    Vaccine; 2011 Sep 22; 29(41):7188-96. PubMed ID: 21651934
    [Abstract] [Full Text] [Related]

  • 19. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
    Bockstal V, Tiemessen MM, Achterberg R, Van Wordragen C, Knaapen AM, Serroyen J, Marissen WE, Schuitemaker H, Zahn R.
    Vaccine; 2018 Nov 12; 36(46):6979-6987. PubMed ID: 30314910
    [Abstract] [Full Text] [Related]

  • 20. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S, Friedland LR, Ensor K, Weston WM, Howe B, Klein NP.
    Pediatr Infect Dis J; 2008 Apr 12; 27(4):341-6. PubMed ID: 18316985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.